Our studies are focused on IL-2 as a potential therapeutic for diabetic retinopathy, as this cytokine binds with high affinity to the heterotrimeric IL-2 receptor, including the alpha subunit (CD25) on T cells and immune cells such as natural killer cells (NK cells) [7]. The gene discussed is IL2; the disease is diabetic retinopathy.